Alnylam Pharmaceuticals, Inc.

Good day, and thank you for standing by. Welcome to the All-Islam Pharmaceuticals fourth quarter 2021 earnings conference call. At this time, all participants are in listen-only mode. After the presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star, then 1 on your telephone keypad. Please be advised, today's conference may be recorded. If you require operator assistance during the call, please press star, then 0. I'd now like to hand the conference over to Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications.

Good morning.

I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at El Nilem. With me today on the phone are Yvonne Greenstreet, Chief Executive Officer, Tolga Tangler, Chief Commercial Officer, Akshay Vaishnav, President, and Jeff Poulton, Chief Financial Officer. For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page of our website, investors.elnilam.com slash events. During today's call, as outlined in slide two, Yvonne will deliver introductory remarks and provide some general context. Tolga will provide an update on our global commercial progress. Akshay will review our recent clinical and preclinical updates And Jeff will review our financials, including 2022 guidance, followed by a summary of our upcoming milestones before we open the call for your questions. I would like to remind you that this call will contain remarks concerning El Nilo's future expectations, plans, and prospects, which constitute forward-looking statements for the purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recently quarterly report on file at the SEC. In addition, any forward-looking statements represent our views only of the date of this recording and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update such statements. With that, I'll now turn the call over to Yvonne.